Trial Profile
Multicenter REtrospective Study to Evaluate coMpliance to Therapy and Drug survIval of Tocilizumab (TCZ) in patientS With Moderate to Severe actIve rheumatOid Arthritis in routiNe Daily Clinical Practice (REMISSION Study).
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 30 May 2013
Price :
$35
*
At a glance
- Drugs Tocilizumab (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Acronyms REMISSION
- Sponsors Roche
- 06 Jul 2012 Actual patient numbers amended from 198 to 197 as reported by ClinicalTrials.gov.
- 21 May 2012 Actual patient number 198 added as reported by ClinicalTrials.gov.
- 21 May 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.